CBIO insider transactions
Crescent Biopharma Inc. (CBIO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for CBIO
- Officer Lynch Ryan sold $8,365 worth of Ordinary Shares (465 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 13,871 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Scientific Officer Pinkas Jan sold $23,171 worth of Ordinary Shares (1,288 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 22,239 units (SEC Form 4) to satisfy withholding obligation4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Bispham Barbara Harlin sold $21,912 worth of Ordinary Shares (1,218 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 19,330 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Financial Officer Scalzo Richard William sold $20,005 worth of Ordinary Shares (1,112 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 20,298 units (SEC Form 4) (tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Medical Officer Im Ellie Eunkyung sold $21,930 worth of Ordinary Shares (1,219 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 22,069 units (SEC Form 4) (withholding obligation)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- President and COO Mcneill Jonathan sold $369,677 worth of Ordinary Shares (20,549 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 139,158 units (SEC Form 4) (for tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Executive Officer Brumm Joshua T sold $761,067 worth of Ordinary Shares (42,305 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 281,212 units (SEC Form 4) (tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Violin Jonathan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Lubner David Charles4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Balcom Alexandra4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Moran Susan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Fairmount Funds Management Llc4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Scientific Officer Pinkas Jan was granted 22,507 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Business Officer Doughty Christopher Grant was granted 22,714 units of Ordinary Shares, increasing direct ownership by 58% to 62,194 units (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Executive Officer Brumm Joshua T was granted 55,117 units of Ordinary Shares, increasing direct ownership by 21% to 323,517 units (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Financial Officer Scalzo Richard William was granted 19,422 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- President and COO Mcneill Jonathan was granted 25,507 units of Ordinary Shares, increasing direct ownership by 19% to 159,707 units (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Medical Officer Im Ellie Eunkyung was granted 21,298 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Lynch Ryan was granted 12,378 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Bispham Barbara Harlin was granted 18,422 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by President and COO Mcneill Jonathan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Brumm Joshua T4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Pinkas Jan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 3 filed by new insider Pinkas Jan3 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Luo Ying acquired 2,840,376 shares (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Ye Weiguo4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Ma Songjiang4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Chen Ruoyu4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- Gni Group Ltd. acquired 63,588,119 shares (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Wu Charles C4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- New insider Ma Songjiang claimed ownership of 2,942,467 shares (SEC Form 3) (Amendment)3/A - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Luo Ying4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Eastling Thomas Wilson4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Usman Nassim4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Ying Han4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Parry Renate4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Chen Ruoyu4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Carmichael Gordon4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Carmichael Gordon3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Ma Songjiang3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Ye Weiguo3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Parry Renate3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Chen Ruoyu3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Ying Han3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Wu Charles C3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- Gni Hong Kong Ltd disposed of 5,371,304 shares, closing all direct ownership in the company (SEC Form 4)4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- New insider Gni Group Ltd. claimed ownership of 6,266,521 shares (SEC Form 3)3 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Miller Seline E. returned 6 units of Series Y Preferred Stock to the company, closing all direct ownership in the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Lawlor Augustine returned 49 units of Series Y Preferred Stock to the company, closing all direct ownership in the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Usman Nassim returned 34 units of Series Y Preferred Stock to the company, closing all direct ownership in the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Gni Group Ltd. returned 6,267 units of Series Y Preferred Stock to the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Hunt Andrea returned 28 units of Series Y Preferred Stock to the company, closing all direct ownership in the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 3: New insider Gni Group Ltd. claimed ownership of 6,266,521 shares3 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Eastling Thomas Wilson3 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 3 filed by new insider Luo Ying3 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Usman Nassim bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 15% to 24,541 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Miller Seline E. bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 100% to 6,500 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Blouse Grant E. bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 53% to 9,417 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Miller Seline E.4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)